Martine E D Chamuleau
Overview
Explore the profile of Martine E D Chamuleau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koppen A, Sikma M, Engels F, Heerma van Voss M, Chamuleau M, Bartelink I, et al.
Br J Clin Pharmacol
. 2025 Mar;
PMID: 40070262
No abstract available.
2.
Ribrag V, Bron D, Rymkiewicz G, Hoelzer D, Jorgensen J, de Armas-Castellano A, et al.
Lancet Haematol
. 2025 Feb;
12(2):e138-e150.
PMID: 39909657
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and...
3.
Zijlstra M, Snijders R, de Boer F, Chamuleau M, Fransen H, Oerlemans S, et al.
Eur J Haematol
. 2025 Jan;
PMID: 39888067
Comprehensive insights are lacking into why patients with hematological malignancies (HMs) receive no cancer-directed treatment. We evaluated socio-demographic and cancer-related characteristics, decision-making rationales, and overall survival in patients with three...
4.
Linschoten M, Geels J, van Werkhoven E, Visser-Wisselaar H, Chamuleau M, Teske A, et al.
Cardiooncology
. 2025 Jan;
11(1):8.
PMID: 39875951
Background: Dexrazoxane has been studied for its ability to prevent anthracycline-induced cardiac dysfunction (AICD) in several trials but its use in clinical practice remains limited. This is related to the...
5.
de Jonge A, Csikos T, Eken M, Bulthuis E, Poddighe P, Roemer M, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596160
In B-cell malignancies, the overexpression of MYC is associated with poor prognosis, but its mechanism underlying resistance to immunochemotherapy remains less clear. In further investigations of this issue, we show...
6.
de Groot F, Dekker T, Doorduijn J, Bohringer S, Brink M, de Groen R, et al.
Eur J Cancer
. 2024 Oct;
213:115068.
PMID: 39427440
Given the rarity of primary central nervous system lymphoma (PCNSL), evaluations of different high-dose methotrexate-(HD-MTX)-based treatment regimens is sparse. This retrospective, multicenter study evaluates clinical characteristics and outcomes (progression-free, overall...
7.
Ferrandez M, Golla S, Eertink J, Wiegers S, Zwezerijnen G, Heymans M, et al.
J Nucl Med
. 2024 Oct;
65(11):1802-1807.
PMID: 39362767
The aim of this study was to validate a previously developed deep learning model in 5 independent clinical trials. The predictive performance of this model was compared with the international...
8.
Maas C, van Klaveren D, Durmaz M, Visser O, Issa D, Posthuma E, et al.
Blood Cancer J
. 2024 Sep;
14(1):157.
PMID: 39266543
First-line treatment for advanced-stage diffuse large B-cell lymphoma (DLBCL) typically involves 6x R-CHOP21 or 6x R-CHOP21 with two additional rituximab administrations (6x R-CHOP21 + 2 R). In contemporary practice, this...
9.
de Jonge A, Bruins W, Duetz C, Korst C, Rentenaar R, Cosovic M, et al.
Haematologica
. 2024 Jul;
109(11):3760-3765.
PMID: 38961740
No abstract available.
10.
Linton K, Vitolo U, Jurczak W, Lugtenburg P, Gyan E, Sureda A, et al.
Lancet Haematol
. 2024 Jun;
11(8):e593-e605.
PMID: 38889737
Background: A standard of care and optimal duration of therapy have not been established for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was to...